Developer docs
API playgroundTry for free, no card

Search company profiles

GeneTx Biotherapeutics

Full company profile

uuid0000lvk

Namestring
GeneTx Biotherapeutics
Legal namestring
GeneTx Biotherapeutics, Inc.
Websiteurl
genetxbio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

GeneTx Biotherapeutics is a biotechnology company founded in 2017 to develop therapeutics for Angelman syndrome, a rare neurogenetic disorder with no approved disease-modifying treatments. The company's core technology centers on gene therapy modalities, including antisense oligonucleotide (ASO) approaches, with GTX-102 (now branded UX143 under Ultragenyx) as its lead clinical-stage candidate targeting Angelman syndrome. GeneTx was acquired by Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) in August 2024 and operates as a wholly-owned subsidiary, leveraging Ultragenyx's integrated rare disease drug development platform spanning discovery, gene therapy manufacturing, and global commercialization infrastructure across 18+ countries.

GeneTx's business model is pre-revenue and clinically-oriented: the company historically financed operations through venture capital, including a $75 million Series A round in 2020 co-led by RA Capital Management and OrbiMed Advisors with participation from Fidelity Management and Research Company, alongside an earlier ~$6.3 million raise in 2018. Its customer segment is narrow by design — Angelman syndrome patients and their caregivers — with planned commercialization expected to flow through Ultragenyx's specialty pharmacy and hospital-based administration channels under the ultra-orphan gene therapy commercial model. Pricing for gene therapies of this class typically ranges $2-3 million per patient as one-time treatments, though GTX-102-specific pricing is not publicly disclosed.

The company's value proposition is rooted in addressing severe unmet medical need in ultra-rare genetic disease, where standard pharmaceutical economics break down but pricing power and regulatory exclusivity are correspondingly high. As a subsidiary of Ultragenyx, GeneTx benefits from its parent's diversified gene therapy pipeline (DTX401, DTX301, UX701, UX111, UX016, UX055), established rare disease advocacy infrastructure (ultrarareadvocacy.com), and operational scale in clinical development and manufacturing. The leadership team — co-founders Allyson Berent (COO) and Paula Evans (CEO), alongside CMO Scott Stromatt — brings rare disease development expertise that anchored the company's clinical progression prior to acquisition.

Short descriptiontext

GeneTx Biotherapeutics, a 2017-founded biotech and wholly-owned subsidiary of Ultragenyx (NASDAQ: RARE) since August 2024, develops gene therapies for Angelman syndrome, a rare neurogenetic disorder with no approved disease-modifying treatments, with lead candidate GTX-102 (now UX143) in clinical development.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersDowners Grove, United States
HQ citystring
Downers Grove
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rare disease therapeutics, gene therapy development, antisense oligonucleotide therapy, Angelman syndrome treatment, neurological genetic diseases
Industry2 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy / Rare Disease Biopharmaceuticals
No data
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GeneTx Biotherapeutics develops GTX-102, an antisense oligonucleotide gene therapy candidate in clinical development for Angelman syndrome, a rare neurogenetic disorder with no currently approved disease-modifying therapies. The company operates as a wholly-owned subsidiary of Ultragenyx Pharmaceutical Inc., focused exclusively on advancing this single therapeutic program targeting the UBE3A gene expression pathway for patients with Angelman syndrome.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • The global gene therapy market was valued at $7.74 billion in 2023 and is projected to exceed $38.76 billion by 2032.
Product and service1 record
1GTX-102 (now UX143)
Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

GeneTx Biotherapeutics is a subsidiary of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Ultragenyx acquired GeneTx in 2020 to expand its rare disease gene therapy pipeline, specifically to advance GTX-102 for Angelman syndrome. GeneTx operates as part of Ultragenyx's integrated platform, leveraging the parent company's development, manufacturing, and commercial capabilities.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Parent company of GeneTx; publicly-traded rare-disease biopharma with an integrated gene-therapy platform, multiple clinical-stage programs across metabolic and neurologic rare diseases, and global commercial infrastructure that GeneTx now leverages for GTX-102 development.

TypeDirect peer
Description

Leader in antisense oligonucleotide (ASO) therapeutics with a deep pipeline in rare neurological and genetic diseases; directly relevant given that GTX-102 is described in funding details as an ASO therapy for Angelman syndrome.

TypeBroad incumbent
Description

Established commercial-stage gene therapy company with FDA-approved AAV-based therapies for rare neuromuscular diseases; comparable as a rare-disease genetic medicine developer with demonstrated regulatory and commercial track record.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on rare CNS and neurodevelopmental disorders using AAV delivery; most directly comparable to GeneTx on indication area (rare CNS monogenic disease) and modality.

TypeEmerging player
Description

Clinical-stage AAV gene therapy developer targeting rare CNS disorders; comparable therapeutic modality and indication focus to GeneTx/GTX-102 for Angelman syndrome.

TypeEmerging player
Description

Gene therapy company developing AAV-delivered regulatory-element-based therapies for severe CNS disorders; overlaps with GeneTx's modality and ultra-rare CNS indication strategy.

TypeEmerging player
Description

Clinical-stage rare-disease biotech focused on neurological and neurodevelopmental disorders; comparable patient population focus and orphan-drug development approach.

TypeBroad incumbent
Description

Established rare-disease biopharma with both small-molecule and gene-therapy programs across CNS and metabolic indications; relevant comparable for a clinical-stage rare-disease asset at the integration/launch stage.

TypeBroad incumbent
Description

Commercial-stage rare-disease biopharma with approved gene and enzyme-replacement therapies (e.g., ROCTAVIAN for hemophilia A); comparable in commercialization of ultra-orphan gene therapies and pricing/reimbursement strategy.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company developing stereopure oligonucleotides for rare neurological and neuromuscular genetic diseases; comparable to GTX-102 if treated as an oligonucleotide-based modality.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GeneTx Biotherapeutics

Gene Therapy / Rare Disease Biopharmaceuticalsgenetxbio.com

GeneTx Biotherapeutics, a 2017-founded biotech and wholly-owned subsidiary of Ultragenyx (NASDAQ: RARE) since August 2024, develops gene therapies for Angelman syndrome, a rare neurogenetic disorder with no approved disease-modifying treatments, with lead candidate GTX-102 (now UX143) in clinical development.

What GeneTx Biotherapeutics does

GeneTx Biotherapeutics is a biotechnology company founded in 2017 to develop therapeutics for Angelman syndrome, a rare neurogenetic disorder with no approved disease-modifying treatments. The company's core technology centers on gene therapy modalities, including antisense oligonucleotide (ASO) approaches, with GTX-102 (now branded UX143 under Ultragenyx) as its lead clinical-stage candidate targeting Angelman syndrome. GeneTx was acquired by Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) in August 2024 and operates as a wholly-owned subsidiary, leveraging Ultragenyx's integrated rare disease drug development platform spanning discovery, gene therapy manufacturing, and global commercialization infrastructure across 18+ countries.

GeneTx's business model is pre-revenue and clinically-oriented: the company historically financed operations through venture capital, including a $75 million Series A round in 2020 co-led by RA Capital Management and OrbiMed Advisors with participation from Fidelity Management and Research Company, alongside an earlier ~$6.3 million raise in 2018. Its customer segment is narrow by design — Angelman syndrome patients and their caregivers — with planned commercialization expected to flow through Ultragenyx's specialty pharmacy and hospital-based administration channels under the ultra-orphan gene therapy commercial model. Pricing for gene therapies of this class typically ranges $2-3 million per patient as one-time treatments, though GTX-102-specific pricing is not publicly disclosed.

The company's value proposition is rooted in addressing severe unmet medical need in ultra-rare genetic disease, where standard pharmaceutical economics break down but pricing power and regulatory exclusivity are correspondingly high. As a subsidiary of Ultragenyx, GeneTx benefits from its parent's diversified gene therapy pipeline (DTX401, DTX301, UX701, UX111, UX016, UX055), established rare disease advocacy infrastructure (ultrarareadvocacy.com), and operational scale in clinical development and manufacturing. The leadership team — co-founders Allyson Berent (COO) and Paula Evans (CEO), alongside CMO Scott Stromatt — brings rare disease development expertise that anchored the company's clinical progression prior to acquisition.

GeneTx Biotherapeutics firmographics

Firmographics
Name
GeneTx Biotherapeutics
Legal name
GeneTx Biotherapeutics, Inc.
Website
https://genetxbio.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
1,001–5,000 employees
Short description
GeneTx Biotherapeutics, a 2017-founded biotech and wholly-owned subsidiary of Ultragenyx (NASDAQ: RARE) since August 2024, develops gene therapies for Angelman syndrome, a rare neurogenetic disorder with no approved disease-modifying treatments, with lead candidate GTX-102 (now UX143) in clinical development.
Ownership category
akta.pro rank

GeneTx Biotherapeutics industry classification

Industry
Product category
Gene Therapy / Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Rare disease therapeutics
  • Gene therapy development
  • Antisense oligonucleotide therapy
  • Angelman syndrome treatment
  • Neurological genetic diseases

Where GeneTx Biotherapeutics is headquartered

Location

Headquarters

HQ city
Downers Grove
HQ country
United States
HQ region
North America

Markets served

GeneTx Biotherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Marketing channels1 record

GeneTx Biotherapeutics product offering

Product offering

Core offering

GeneTx Biotherapeutics develops GTX-102, an antisense oligonucleotide gene therapy candidate in clinical development for Angelman syndrome, a rare neurogenetic disorder with no currently approved disease-modifying therapies. The company operates as a wholly-owned subsidiary of Ultragenyx Pharmaceutical Inc., focused exclusively on advancing this single therapeutic program targeting the UBE3A gene expression pathway for patients with Angelman syndrome.

Differentiator

Problem solved

Functional benefit

Products and services

  • GTX-102 (now UX143)

Quantifiable outcome

  • The global gene therapy market was valued at $7.74 billion in 2023 and is projected to exceed $38.76 billion by 2032.

Companies that use GeneTx Biotherapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

GeneTx Biotherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

GeneTx Biotherapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • UltragenyxcoreStrategic or Co-development PartnerGeneTx Biotherapeutics is a subsidiary of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Ultragenyx acquired GeneTx in 2020 to expand its rare disease gene therapy pipeline, specifically to advance GTX-102 for Angelman syndrome. GeneTx operates as part of Ultragenyx's integrated platform, leveraging the parent company's development, manufacturing, and commercial capabilities.

Recent moves5 records

Expansion highlights5 records

GeneTx Biotherapeutics competitors and assessment

Company assessment

Broad incumbents

  • Ultragenyx Pharmaceutical: Parent company of GeneTx; publicly-traded rare-disease biopharma with an integrated gene-therapy platform, multiple clinical-stage programs across metabolic and neurologic rare diseases, and global commercial infrastructure that GeneTx now leverages for GTX-102 development.
  • Sarepta Therapeutics: Established commercial-stage gene therapy company with FDA-approved AAV-based therapies for rare neuromuscular diseases; comparable as a rare-disease genetic medicine developer with demonstrated regulatory and commercial track record.
  • PTC Therapeutics: Established rare-disease biopharma with both small-molecule and gene-therapy programs across CNS and metabolic indications; relevant comparable for a clinical-stage rare-disease asset at the integration/launch stage.
  • BioMarin Pharmaceutical: Commercial-stage rare-disease biopharma with approved gene and enzyme-replacement therapies (e.g., ROCTAVIAN for hemophilia A); comparable in commercialization of ultra-orphan gene therapies and pricing/reimbursement strategy.

Direct peers

  • Ionis Pharmaceuticals: Leader in antisense oligonucleotide (ASO) therapeutics with a deep pipeline in rare neurological and genetic diseases; directly relevant given that GTX-102 is described in funding details as an ASO therapy for Angelman syndrome.
  • Taysha Gene Therapies: Clinical-stage gene therapy company focused on rare CNS and neurodevelopmental disorders using AAV delivery; most directly comparable to GeneTx on indication area (rare CNS monogenic disease) and modality.

Emerging players

  • Passage Bio: Clinical-stage AAV gene therapy developer targeting rare CNS disorders; comparable therapeutic modality and indication focus to GeneTx/GTX-102 for Angelman syndrome.
  • Encoded Therapeutics: Gene therapy company developing AAV-delivered regulatory-element-based therapies for severe CNS disorders; overlaps with GeneTx's modality and ultra-rare CNS indication strategy.
  • Ovid Therapeutics: Clinical-stage rare-disease biotech focused on neurological and neurodevelopmental disorders; comparable patient population focus and orphan-drug development approach.
  • Wave Life Sciences: Clinical-stage RNA therapeutics company developing stereopure oligonucleotides for rare neurological and neuromuscular genetic diseases; comparable to GTX-102 if treated as an oligonucleotide-based modality.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

GeneTx Biotherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GeneTx Biotherapeutics leadership team

Management profile

Number of profiles

Profiles3 records

GeneTx Biotherapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GeneTx Biotherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneTx Biotherapeutics

What does GeneTx Biotherapeutics do?

GeneTx Biotherapeutics develops GTX-102, an antisense oligonucleotide gene therapy candidate in clinical development for Angelman syndrome, a rare neurogenetic disorder with no currently approved disease-modifying therapies. The company operates as a wholly-owned subsidiary of Ultragenyx Pharmaceutical Inc., focused exclusively on advancing this single therapeutic program targeting the UBE3A gene expression pathway for patients with Angelman syndrome.

Is GeneTx Biotherapeutics a public or private company?

GeneTx Biotherapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was GeneTx Biotherapeutics founded?

GeneTx Biotherapeutics was founded in 2017. It employs 1,001 to 5,000 people.

Where is GeneTx Biotherapeutics based?

GeneTx Biotherapeutics is headquartered in Downers Grove, United States, in the North America region.

Who are GeneTx Biotherapeutics's main competitors?

Broad incumbents on record are Ultragenyx Pharmaceutical, Sarepta Therapeutics, PTC Therapeutics and BioMarin Pharmaceutical. Direct peers are Ionis Pharmaceuticals and Taysha Gene Therapies. Emerging players are Passage Bio, Encoded Therapeutics, Ovid Therapeutics and Wave Life Sciences.

Does GeneTx Biotherapeutics have an API?

No public API is recorded for GeneTx Biotherapeutics.

What industry is GeneTx Biotherapeutics in?

GeneTx Biotherapeutics's product category is Gene Therapy / Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Labiotech.euNew names, new narratives: Why biotechs decide to rebrandGalapagos rebranded as Lakefront Biotherapeutics after winding down its cell therapy business, incurring €150-200 million in restructuring costs. Hoth Therapeutics pivoted to space and AI, becoming Rocket One, with shares jumping nearly 40%. Molecular Health's Dataome business launched as Lucera, focusing on decision intelligence.MarketScreenerMerck KGaA lifts 2026 profit outlook on demand for lab suppliesMerck KGaA raised its 2026 adjusted operating profit guidance to 5.7-6.1 billion euros, citing stronger lab supply demand and Mavenclad competition. The guidance beats the prior range and lifts shares 8% to a two-month high. First-quarter adjusted EBITDA slipped 0.3% to 1.53 billion euros, beating expectations.GlobeNewswireMilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene TherapiesMilliporeSigma signed a five-year agreement with Genetix Biotherapeutics to provide analytical and biosafety testing for its three FDA-approved gene therapies. The therapies treat sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. The partnership builds on over a decade of collaboration.GenengnewsGenetic Agency on Display at GATC 2025Dyno Therapeutics hosted the Genetic Agency Technology Conference (GATC) 2025 in Boston on November 11, bringing together researchers, executives, patients, and advocates in cell and gene therapy to discuss collaboration in delivering therapies. The conference featured patient advocates including Sonia Vallabh, who is developing a therapy for her own prion disease targeting first patient dosing in early 2026, and Victoria Gray, the first sickle cell patient to receive CRISPR therapy in 2019 who shared her inspirational story of being symptom-free for 6.5 years. Dyno announced an improved AAV capsid for muscle targeting, AI agent platform updates, and expanded manufacturing partnerships, while FAST's Allyson Berent reported six Angelman syndrome programs now in the clinic following Ultragenyx's acquisition of GeneTx BioTherapeutics.BenzingaUltragenyx's Neurogenetic Disorder Candidate Shows Favorable Tolerability, Clinical Activity - UltragenyxUltragenyx Pharmaceutical and GeneTx Biotherapeutics announced interim data from a Phase 1/2 study showing favorable tolerability and clinical activity in pediatric patients with Angelman syndrome. Concurrently, Ultragenyx closed its acquisition of GeneTx for an upfront payment of $75 million plus future milestones, while also securing regulatory approval to expand the study with higher-dose patient cohorts.SfariFrom parent advocate to nonprofit chief science officer, to biotherapeutic company cofounder — A personal journey through drug development for Angelman syndromeAllyson Berent, after her daughter was diagnosed with Angelman syndrome at 5.5 months, became chief science officer of FAST and cofounder of GeneTx Biotherapeutics. The company completed the FDA's IND program in 13 months, enabling first-in-human studies. The company aims to develop an antisense oligonucleotide for Angelman syndrome.PR NewswireGeneTx Announces IRB Approval to Begin Clinical Study of GTX-102 for the Treatment of Angelman SyndromeGeneTx Biotherapeutics LLC received IRB approval from Rush University Medical Center to begin the KIK-AS Phase 1/2 clinical study of GTX-102, an experimental antisense oligonucleotide being evaluated for Angelman syndrome. The open-label, multiple-dose, dose-escalating study will enroll approximately 20 pediatric patients aged 4 to 17 years with genetically confirmed full maternal UBE3A gene deletion at Rush University in Chicago, with additional clinical sites planned for Boston, Cincinnati, Denver, Los Angeles, New York, and Ottawa, Canada. GeneTx has partnered with Ultragenyx Pharmaceutical, which holds an exclusive option to acquire GeneTx, and GTX-102 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.GlobeNewswireGeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatmentThe FDA granted orphan-drug designation to GeneTx Biotherapeutics' GTX-101 for Angelman syndrome, the company's first drug candidate. The antisense oligonucleotide targets the UBE3A gene, and the designation provides incentives like marketing exclusivity and tax credits.GlobeNewswireNew biotech launched for antisense program targeting Angelman syndromeFAST launched GeneTx Biotherapeutics to develop and commercialize GTX-101, an antisense drug for Angelman syndrome. The company entered a worldwide license agreement with Texas A&M University System and a research collaboration with Texas A&M AgriLife Research. No approved therapeutics exist for Angelman syndrome.